Deep brain stimulation
DeviceDeep brain stimulation of the centromedian nucleus (bilateral)
NCT Number: NCT05437393
The CADET Pilot will investigate the safety and feasibility of deep brain stimulation (DBS) to treat children with Lennox-Gastaut syndrome using a novel DBS device (Picostim DyNeuMo-1).
Following a 30-day preoperative/baseline assessment phase, all children will have a neurosurgical procedure to implant the device. Implantation will be followed by a 30-day phase of no stimulation (the device is off / inactive) and then a six-month phase of active stimulation (the device is on / active).
Looking for future studies?
Notify Me5 year–14 year
All sexes
Interventional
Not applicable
Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom
The CADET pilot will be a single-arm, multi-site, interventional clinical trial. This design has been chosen since this is a feasibility and safety trial in a small number of patients and thus does not primarily aim to determine efficacy.
In this pilot clinical trial, four children with drug-resistant LGS will undergo bilateral CMN DBS.
Following the DBS insertion, all children will undergo one month of inactive ('off') DBS in order to allow the lesioning effect of electrode implantation to dissipate. Thereafter, children will receive active ('on') DBS therapy with standard stimulation parameters for six-months. Following the 'on' phase of the trial, the child will then transition into continuing clinical care and will have their stimulation parameters altered according to clinical evaluation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Children enrolled in this study must:
-------------------------------
Exclusion criteria
Children enrolled in this study must not:
Deep brain stimulation of the centromedian nucleus (bilateral)
Time frame: Following 6-months of active stimulation
Measured according to pre-determined device-related AEs and SAEs, as well as generic AEs and SAEs.
Time frame: Following 6-months of active stimulation
Consent at baseline
Time frame: Following 6-months of active stimulation
Completion of all study activities at study exit
Time frame: Following 6-months of active stimulation
Device recharging is measured using the Picostim event logs
Time frame: Following 6-months of active stimulation (compared to baseline)
Measured using parent-reported diaries
Time frame: Following 6-months of active stimulation (compared to baseline)
Measured using serial electroencephalography (EEG)
Time frame: Following 6-months of active stimulation (compared to baseline)
Measured using the Hague Seizure Severity Scoring questionnaire. Minimum score = 13; maximum score = 52; with higher seizure severity with ascending values.
Time frame: Following 6-months of active stimulation (compared to baseline)
Measured on the Pediatric Quality of Life Inventory (PedsQL) questionnaire. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.
Time frame: Following 6-months of active stimulation (compared to baseline)
Measured on the Impact of Pediatric Epilepsy Scale (IPES) questionnaires. The minimum score is 0 and the maximum score is 100, with improving quality of life with ascending values.
Time frame: Following 6-months of active stimulation
Analysis of pre-trial MRI brain scan in conjunction with relative change in seizure counts measured using parent-reported diaries
Time frame: Following 6-months of active stimulation
Analysis of local-field potentials measured from the DBS device in conjunction with data from the encephalography (EEG) data
University College, London
Other
Acronym: CADET Pilot
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05339126
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02224560
Brain Diseases, Central Nervous System Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02224690
Brain Diseases, Central Nervous System Diseases
Tampa, Florida, United States
View Trial DetailsNCT02224573
Brain Diseases, Central Nervous System Diseases
View Trial Details